Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of -1.450–1.450 for the period, compared to the consensus earnings per share estimate of -0.590. The company issued revenue guidance of $350.0 million-$350.0 million, compared to the consensus revenue estimate of $343.6 million.

Fulgent Genetics Trading Down 38.1%

FLGT stock traded down $9.43 during trading on Friday, reaching $15.33. 2,378,279 shares of the stock were exchanged, compared to its average volume of 262,199. The business has a 50 day moving average price of $25.91 and a 200-day moving average price of $24.87. Fulgent Genetics has a 1 year low of $14.57 and a 1 year high of $31.04. The firm has a market capitalization of $473.85 million, a price-to-earnings ratio of -11.03 and a beta of 0.86.

Analysts Set New Price Targets

FLGT has been the subject of several analyst reports. Zacks Research lowered Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Wall Street Zen lowered shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Raymond James Financial reaffirmed an “outperform” rating and set a $36.00 target price on shares of Fulgent Genetics in a research note on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Finally, Piper Sandler lifted their target price on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Fulgent Genetics has a consensus rating of “Hold” and a consensus price target of $32.00.

Insider Activity at Fulgent Genetics

In other Fulgent Genetics news, insider Hanlin Gao sold 1,075 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total value of $30,454.75. Following the completion of the transaction, the insider owned 952,890 shares of the company’s stock, valued at $26,995,373.70. This trade represents a 0.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Jian Xie sold 1,140 shares of the business’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $28.33, for a total transaction of $32,296.20. Following the completion of the transaction, the chief operating officer owned 336,749 shares of the company’s stock, valued at approximately $9,540,099.17. This trade represents a 0.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 31.76% of the stock is owned by corporate insiders.

Institutional Trading of Fulgent Genetics

Hedge funds have recently added to or reduced their stakes in the company. RTW Investments LP purchased a new position in shares of Fulgent Genetics during the fourth quarter worth about $18,521,000. JPMorgan Chase & Co. boosted its position in shares of Fulgent Genetics by 767.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock valued at $6,758,000 after purchasing an additional 264,524 shares during the period. Goldman Sachs Group Inc. grew its stake in Fulgent Genetics by 89.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 348,533 shares of the company’s stock worth $9,156,000 after buying an additional 164,535 shares during the last quarter. Wells Fargo & Company MN increased its position in Fulgent Genetics by 261.1% during the fourth quarter. Wells Fargo & Company MN now owns 120,781 shares of the company’s stock worth $3,173,000 after buying an additional 87,329 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Fulgent Genetics in the fourth quarter valued at approximately $2,177,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.